Company intelligence / Profile preview

Helex

Bengaluru, Karnataka, India

Ownership: Private
Development stage: Other

Overview

Helex is a biotechnology company developing next-generation CRISPR-based gene editing therapies for rare genetic and metabolic diseases. The company's proprietary platform focuses on creating one-time curative treatments by precisely modifying disease-causing genes within the body. Its lead programs target Primary Hyperoxaluria Type 1 (PH1), aiming to reduce toxic metabolite accumulation by silencing key enzymes such as Hydroxyacid oxidase 1. Based in Bengaluru, Helex leverages advanced genome engineering to address significant unmet medical needs in inherited disorders. The company has received backing from prominent global accelerators and venture firms, including SOSV and IndieBio.

Therapeutic areas: Rare Diseases
Modalities: CRISPR-based therapyGene therapy
Industry: Biotech

Beyond the preview

Go deeper on Helex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Helex.

Explore the full profile